Platinum Investment Management Ltd. Has $3.82 Million Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Platinum Investment Management Ltd. increased its stake in Centessa Pharmaceuticals by 8.6% to own approximately 0.22% of the company, valued at $3.82 million.
• Centessa Pharmaceuticals' shares have seen a 6.7% decline in value, with current trading at $22.62 after a 12-month high of $24.57.
• Insider trading included significant sales from CEO Saurabh Saha and other executives, totaling 205,286 shares valued at nearly $4 million in the last quarter.

Platinum Investment Management Ltd. grew its holdings in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 8.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 290,836 shares of the company's stock after acquiring an additional 22,949 shares during the period. Platinum Investment Management Ltd. owned 0.22% of Centessa Pharmaceuticals worth $3,822,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd grew its stake in Centessa Pharmaceuticals by 15,209.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after purchasing an additional 3,194 shares during the period. Osterweis Capital Management Inc. acquired a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $47,000. Bank of New York Mellon Corp acquired a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $147,000. Fox Run Management L.L.C. acquired a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $160,000. Finally, Vestal Point Capital LP acquired a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $214,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Stock Down 6.7%

Shares of NASDAQ:CNTA opened at $22.62 on Thursday. The stock has a market cap of $3.03 billion, a price-to-earnings ratio of -12.64 and a beta of 1.56. The company has a quick ratio of 10.12, a current ratio of 10.11 and a debt-to-equity ratio of 0.32. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $9.60 and a 12-month high of $24.57. The business's 50 day moving average is $18.81 and its 200 day moving average is $15.24.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.03). On average, sell-side analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Mario Alberto Accardi sold 8,322 shares of the business's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $15.23, for a total value of $126,744.06. Following the transaction, the insider owned 208,163 shares in the company, valued at $3,170,322.49. The trade was a 3.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $15.92, for a total value of $875,600.00. Following the completion of the transaction, the chief executive officer owned 221,017 shares in the company, valued at $3,518,590.64. The trade was a 19.93% decrease in their position. The disclosure for this sale can be found here. Insiders sold 205,286 shares of company stock valued at $3,993,345 in the last quarter. 7.09% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

CNTA has been the subject of a number of research reports. Wells Fargo & Company initiated coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, September 3rd. They issued an "overweight" rating and a $31.00 price target for the company. Chardan Capital restated a "buy" rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a research note on Tuesday, August 12th. Oppenheimer initiated coverage on Centessa Pharmaceuticals in a research note on Friday, August 29th. They issued an "outperform" rating and a $40.00 target price for the company. Lifesci Capital raised Centessa Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, September 3rd. Finally, Wall Street Zen cut Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. One equities research analyst has rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the stock. Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of "Buy" and an average target price of $32.38.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.